Adverse Events Associated With Anti-IL-23 Agents: Clinical Evidence and Possible Mechanisms [PDF]
Frontiers in Immunology, 2021 BackgroundAnti-interleukin (IL)-23 agents are widely used for autoimmune disease treatment; however, the safety and risks of specific symptoms have not been systematically assessed.ObjectivesThe aim of this study was to summarize the characteristics and ...
Yi Ru +26 more
doaj +6 more sources
Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis. [PDF]
Drug Des Devel Ther, 2018 Risankizumab, a fully human IgG monoclonal antibody inhibitor of IL-23, is a therapeutic agent currently in late stage development for use in the treatment of moderate-to-severe plaque psoriasis.
Haugh IM +3 more
europepmc +8 more sources
Leptin: a gender and obesity-related marker predictive of metabolic comorbidities and therapeutic response to anti-IL-23 biologic drugs in psoriatic patients [PDF]
Frontiers in ImmunologyIntroductionPsoriasis is a chronic immune-mediated inflammatory skin disorder, frequently associated with comorbidities such as obesity, which can exacerbate its severity and hinder treatment efficacy. Psoriasis pathogenesis involves complex interactions
Roberta Belli +21 more
doaj +3 more sources
Intraperitoneal administration of the anti-IL-23 antibody prevents the establishment of intestinal nematodes in mice. [PDF]
Sci Rep, 2018 Previous studies have established that an increased Th-9 response creates a hostile environment for nematode parasites. Given that IL-23, a cytokine required for maintenance of the IL-17–secreting phenotype, has inhibitory effects on IL-9 production, we ...
Gomez-Samblas M +7 more
europepmc +8 more sources
Structural Basis for p19 Targeting by Anti-IL-23 Biologics: Correlations with Short- and Long-Term Efficacy in Psoriasis. [PDF]
JID InnovIL-23 is central to psoriasis pathogenesis. Biologics targeting IL-23 are important therapies against psoriasis. IL-23 inhibitors risankizumab, tildrakizumab, and guselkumab bind the IL-23 p19 subunit, whereas ustekinumab binds p40; however, the ...
Daniele SG +4 more
europepmc +5 more sources
Rare pediatric Saccharomyces cerevisiae fungemia with neutralizing anti-IL-23 autoantibodies: a case report [PDF]
BMC PediatricsAnti-IL-23 autoantibodies are associated with severe, persistent opportunistic infections. We described the first pediatric case of Saccharomyces cerevisiae fungemia with high anti-IL-23 autoantibodies, which was successfully treated using the novel ...
Yajuan Zhou +3 more
doaj +5 more sources
Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. [PDF]
Journal of Clinical Investigation, 2006 IL-23 is a member of the IL-12 cytokine family that drives a highly pathogenic T cell population involved in the initiation of autoimmune diseases. We have shown that IL-23-dependent, pathogenic T cells produced IL-17 A, IL-17 F, IL-6, and TNF but not IFN-gamma or IL-4.
Yi Chen +12 more
semanticscholar +3 more sources
Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis. [PDF]
Drug Des Devel Ther, 2019 The approval of guselkumab marks the entry of the IL-23 inhibitor class into the therapeutic armamentarium for patients with moderate-to-severe plaque psoriasis. This class specifically targets the upstream portion of the type 17 helper T (Th17) axis, which has been implicated as a key driver of the abnormal inflammatory state observed in psoriasis ...
Yang EJ, Smith MP, Ly K, Bhutani T.
europepmc +6 more sources
Anti-IL-23 exerted protective effects on cerebral ischemia–reperfusion injury through JAK2/STAT3 signaling pathway [PDF]
Molecular Biology Reports, 2020 Ischemia–reperfusion frequently occurs in ischemic cerebral vascular disease, during which the inflammatory signaling plays essential roles. The aim of this study was to discover the efficacy of the antibody to a key immune cytokine IL-23 (anti-IL-23 ...
Lichao Fan, Lichun Zhou
semanticscholar +4 more sources
Circulating MicroRNAs in Patients with Psoriasis Treated with Anti-IL-23: A Cohort Study. [PDF]
Dermatol Ther (Heidelb)Psoriasis is characterized by aberrant keratinocyte activity and immune cell infiltration, driven by immune-mediated pathways. MicroRNAs (miRNAs) play crucial roles in regulating these processes, offering insights into disease mechanisms and therapeutic targets.This study aimed to investigate changes in circulating miRNAs in psoriasis patients ...
Diotallevi F +11 more
europepmc +6 more sources